Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients

Loading...
Loading...

Amryt Pharma Plc AMYT has presented long-term from the 2nd year open-label extension (OLE) of its Phase 3 OPTIMAL trial of Mycapssa (octreotide capsules in acromegaly.

  • The trial compared long-term safety and efficacy data of Mycapssa to placebo for maintenance of biochemical response in patients with acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone during adulthood.
  • The data demonstrated that 100% of evaluable patients who entered the 2nd year OLE phase of the study as responders - insulin-like growth factor 1 (IGF-1) within normal limits - maintained their long-term biochemical response at the end of the study.
  • Related: Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus.
  • IGF-1 levels were stably maintained within normal limits at the end of the OLE period.
  • Growth hormone (GH) levels also improved at the end of the OLE period.
  • The long-term safety profile of Mycapssa during the OLE was consistent with that observed in prior studies.
  • Price Action: AMYT shares are up 1.97% at $7.76 during the market session on the last check Wednesday.
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...